NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Now where have we heard that name before? Martin van den Bent sounds familiar. . . Oh, that’s right, he and Wick also wrote another hit job on DCVax when the interim results were published in the JTM:

First results on the DCVax phase III trial: raising more questions than providing answers.
Wick W1, van den Bent MJ2
Author information
Neuro-oncology, 01 Sep 2018


In today’s pathetic and false critique in Neuro-Oncology he notes this:

MvdB has received honoraria for consultancy from Genenta, Servier, Astra Zeneca, Boehringer- Ingelheim, Carthera, Nerviano, Chimerix, Roche, Fore Biotherapeutics, Menarini-Stemline, Incyte and Sumitomo Pharma Oncology.

But somehow he just so happened to “forget” that he was paid by Karyopharm for a competing trial that published results earlier this year.

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Authors’ Disclosures
M.J. van den Bent reports personal fees from Karyopharm during the conduct of the study, as well as personal fees from AbbVie outside the submitted work.

https://pure.eur.nl/en/publications/a-phase-ii-study-of-the-efficacy-and-safety-of-oral-selinexor-in-